Home > Healthcare & Medical Devices > Frontotemporal Disorders Treatment Market
Frontotemporal Disorders Treatment Market size is projected to register commendable progress during the forecast period of 2023-2032. Cases of frontotemporal disorders (FTDs) are growing at a significant rate across the world. This has given rise to several brain disorders, including Alzheimer’s and dementia among the elderly population.
According to the Alzheimer’s Association, in 2022, over 6 million American citizens were suffering from Alzheimer’s. This number is predicted to reach 13 million by 2050. As per the U.S. Department of Health and Human Service (HHS), FTDs occur at a relatively younger age, which is unlike other forms of dementia, with around 60% of patients falling in the age category of 45-64 years. Such factors are stimulating the development of frontotemporal disorders treatment market.
Governments and medical agencies across the world are also introducing a wide range of financial grants to support the development of advanced drugs and devices to effectively treat frontotemporal diseases. For example, in November 2022, the U.S. Food and Drug Administration (FDA) introduced its Rare Neurodegenerative Disease Grant Program after passing the Accelerating Access to Critical Therapies for ALS Act. This program will offer grants and contracts to private and public organizations to cover costs associated with R&D for diagnosing, preventing, treating, mitigating, or curing ALS and other rare neurodegenerative disorders in children and adults. Such initiatives are expected to positively influence the frontotemporal disorders treatment market dynamics.
Based on disease, frontotemporal disorders treatment industry is divided into primary progressive aphasia (PPA), behavioral variant frontotemporal dementia, and motor decline. The industry size from the behavioral variant frontotemporal dementia (bvFTD) segment is anticipated to record a notable CAGR through 2032. One of the major factors driving the industry expansion is the emerging need for better care and supervision of patients suffering from this ailment.
Ongoing research regarding the creation of innovative treatments to manage the symptoms of FTDs is likely to fuel industry development. For instance, in May 2022, a study led by Monash University revealed a promising treatment with the potential to stabilize the behavioral issues associated with bvFTD. The new drug also demonstrated the ability to slow brain shrinkage and cognitive decline caused by this condition. Such product launch initiatives are expected to influence market trends.
In terms of drug class, the global frontotemporal disorders treatment market share from the antidepressant segment is expected to grow at a steady rate during the analysis timeframe. These drugs are being widely prescribed by doctors as they can control a patient’s cortisol levels and behavioral symptoms associated with FTDs, including depression, social anxiety, and dysthymia. New drug launches are also predicted to fuel product consumption.
North America frontotemporal disorders treatment industry is likely to witness a robust CAGR during the analysis timeline, given the high-quality healthcare infrastructure and rising cases of dementia and other neurodegenerative disorders.
AstraZeneca, Eli Lilly & Co., Allergan, GlaxoSmithKline, Johnson & Johnson, Sanofi, Merck, Pfizer, and Mylan are some of the prominent industry players. These companies are utilizing various strategies, including partnerships, mergers, acquisitions, and product launches to strengthen their competitive edge.